45th week of 2012 patent applcation highlights part 33 |
Patent application number | Title | Published |
20120282166 | WATER REACTIVE HYDROGEN GENERATION SYSTEM AND METHOD WITH SEPARATION OF WASTE PRODUCTS FROM WATER REACTIVE MATERIALS - A water reactive hydrogen generation system includes devices and methods to combine reactant fuel materials and aqueous solutions to generate hydrogen. The generated hydrogen is used in a fuel cell or other application. The water reactive hydrogen generation system includes a reactant fuel chamber, a reactor chamber (zone), a water solution inlet, a hydrogen output port, and a material delivery device. The material delivery device can include a drive screw and a sliding piston to move the fuel material into the reactor zone when a reaction is initiated. As the reaction takes place, the reaction waste product is removed from the reaction zone to allow additional reactant fuel materials and aqueous solutions to be introduced and to continue the hydrogen-generating reaction. A reaction waste product created is exchanged for additional reactant fuel material at determined intervals to allow the reaction to continue until the reactant fuel is exhausted. | 2012-11-08 |
20120282167 | METHOD FOR PREDICTING THE SENSITIVITY OF A TUMOR TO AN EPIGENETIC TREATMENT - The present invention provides a method for determining the RES phenotype in a tumor. The present invention further provides a method for predicting the sensitivity of a tumor to an epigenetic treatment, the method comprising determining the RES phenotype in said tumor, the presence of the RES phenotype in a tumor being indicative of a tumor sensitive to an epigenetic therapy. The present invention also provides a method for diagnosing an aggressive tumor and for selecting a patient affected with a tumor for an epigenetic therapy. | 2012-11-08 |
20120282168 | METHODS OF SENSITIZING CANCER TO THERAPY-INDUCED CYTOTOXICITY - The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer cells can be either therapy-sensitive or therapy resistant. The present application further demonstrates that Salinosporamide A induces the expression of Raf kinase inhibitor protein (RKIP) and PTEN, tumor suppressor proteins, and inhibits the expression of YY1, a transcriptional regulator protein overexpressed in cancer cells and also inhibits the growth factor pleiotrophin (PTN). | 2012-11-08 |
20120282169 | DETECTION AND TREATMENT OF TRAUMATIC BRAIN INJURY - The present invention relates to the detection of traumatic brain injury by detecting Aβ protein aggregates associated with traumatic brain injury. These Aβ protein aggregates are detected using peptide and peptide mimic probes that preferentially associate with Aβ protein aggregates associated with traumatic brain injury. | 2012-11-08 |
20120282170 | ANTI- TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods. | 2012-11-08 |
20120282171 | RADIOLABELLING METHODS - The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): | 2012-11-08 |
20120282172 | TARGETED DELIVERY TO HUMAN DISEASES AND DISORDERS - The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders. | 2012-11-08 |
20120282173 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT - An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers. | 2012-11-08 |
20120282174 | Synergistic Anti-CD47 Therapy for Hematologic Cancers - Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2. | 2012-11-08 |
20120282175 | Methods for Increasing Efficacy of FOLR1 Cancer Therapy - Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided. | 2012-11-08 |
20120282176 | Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier - Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC | 2012-11-08 |
20120282177 | ROR1 as Therapeutic and Diagnostic Target - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, skin cancer and thyroid cancer. | 2012-11-08 |
20120282178 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 2012-11-08 |
20120282179 | Methods of Using C-Met Modulators - Methods of treating cancer by administering a compound of Formula I, | 2012-11-08 |
20120282180 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof - The present invention relates to the field of therapeutic and diagnostic agents and more specifically to compounds of formula (I) that are inhibitors of matrix-metalloproteinases (MMPs) and are useful in the treatment of diseases related thereto such as cardiovascular diseases, inflammatory diseases and malignant diseases. One embodiment of the invention is a compound of formula (I) labeled with a 18-fluorine atom having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the inhibitors of matrix-metalloproteinases (MMPs) of the invention or the corresponding labeled compounds useful as diagnostic imaging agents of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the inhibitors of matrix-metalloproteinases (MMPs) of the invention and of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. | 2012-11-08 |
20120282181 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with Mtb in a subject are disclosed. The methods include detecting the presence of CD8 | 2012-11-08 |
20120282182 | NANOPARTICLE CLUSTERS FORMED FROM INDIVIDUAL NANOPARTICLES OF TWO OR MORE TYPES - Nanoparticle clusters are described. In particular nanoparticle clusters formed from two or more individual nanoparticles of different types are described and methods for fabricating such nanoparticle clusters are further described. These nanoparticle clusters are fabricated by surface activating individual ones of the plurality of nanoparticles by desorption of surfactant molecules from the surface of the coated nanoparticles through exposure of the individual ones of the plurality of nanoparticles to an activating agent. | 2012-11-08 |
20120282183 | PROGNOSTIC,. SCREENING AND TREATMENT METHODS AND AGENTS FOR TREATMENT OF METASTASIS AND INFLAMMATION USING 5T4 ONCOFOETAL GLYCOPROTEIN - Methods and agents are disclosed based on the finding that 5T4 interacts with CXCR4 in the cell membrane to form a complex, and that the 5T4 transmembrane region is involved in the promotion of CXCR4 membrane expression and chemotactic response. | 2012-11-08 |
20120282184 | TREATMENT OF OBESITY - A method for the prevention or treatment of a condition selected from type 2 diabetes, obesity and metabolic syndrome comprising activating a GITRL pathway. Methods for screening for substances to treat these conditions, diagnosing or predicting these conditions and selecting and monitoring therapies. | 2012-11-08 |
20120282185 | PARTICLES FOR THE TREATMENT OF CANCER IN COMBINATION WITH RADIOTHERAPY - The invention provides a particle comprising a metal oxide which is doped with at least one rare earth element, wherein the metal oxide is selected from titanium dioxide, zinc oxide, cerium oxide and mixtures of two or more thereof. The invention also provides a pharmaceutical composition comprising the particles, and to uses of the particles and composition in the treatment and diagnosis of cancer. | 2012-11-08 |
20120282186 | TEMPLATED NANOCONJUGATES - The present disclosure is directed to compositions comprising templated nanoconjugates and methods of their use. | 2012-11-08 |
20120282187 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 2012-11-08 |
20120282188 | COSMETIC PRODUCT - A cosmetic product includes at least: a first anhydrous cosmetic composition including at least colouring particles that are solid at room temperature and atmospheric pressure, the particles being formed from: at least one hydrophilic dyestuff in a content of greater than or equal to 60% by weight relative to their total weight, at least one effervescent system in a content of less than or equal to 20% by weight relative to their total weight, at least one hydrophilic binder, and at least one dispersant that is different from the hydrophilic binder; and a second composition comprising at least one aqueous phase. | 2012-11-08 |
20120282189 | Improved Medicinal Aerosol Formulations - The present invention provides a medicinal aerosol suspension formulation for MDI administration, comprising: a) micronised pa-agonist; b) micronised corticosteroid; c) a siib-therapexrtic quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant. | 2012-11-08 |
20120282190 | COMPOSITIONS, METHODS, AND KITS COMPRISING A DRY SHAMPOO COMPOSITION - The present invention relates to compositions, methods, and kits comprising a dry shampoo composition. In some cases, a dry shampoo composition is provided as an aerosol. A dry shampoo composition may comprise at least one clay material, at least one starch material, and at least one carrier material. The composition may additional comprise one or more additive components, such as an oil-absorbing compound, a suspending agent compound, and/or a perfume. | 2012-11-08 |
20120282191 | ORALLY DISPERSIBLE TABLET - The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture. | 2012-11-08 |
20120282192 | ORAL CARE COMPOSITIONS - The present invention relates to oral care compositions with improved flavor release characteristics and improved taste, and methods of using the same. | 2012-11-08 |
20120282193 | AGENT FOR THE PREVENTION AND TREATMENT OF THE INITIAL DENTAL CARIES - A composition for the prevention and treatment of initial tooth caries, that is composed of a phosphate-calcium gel with the Ca/P mass ratio ranging from 1.2 to 1.5 and with a bond energy of the 2p phosphorus electron of 131 eV to 136 eV and optionally containing at least one auxiliary dental substance. The composition can further contain an aqueous solution of methyl cellulose or/and chlorohexidine gluconate. | 2012-11-08 |
20120282194 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS - Disclosed are topical skin compositions and corresponding methods for their use that include plant extracts. One such composition can include a TNF-α inhibitor, wherein said inhibitor is an aqueous extract from the whole plant of | 2012-11-08 |
20120282195 | Topical Skin Care Formulations Comprising Plant Extracts - Disclosed is a topical skin composition and corresponding methods for its use that includes a first MMP-1 inhibitor, wherein said first inhibitor is an extract from | 2012-11-08 |
20120282196 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE - Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided. Methods of inhibiting proliferation of a diseased cell, treating or preventing cancer, treating a neoplasm or psoriasis, and inhibiting the expression of genes involved in the Hedgehog signaling pathway, thereby inhibiting the Hedgehog signaling pathway, are furthermore provided by the invention. | 2012-11-08 |
20120282197 | USE OF PIPERIDINE ESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT - The present invention relates to the use of at least one piperidine ester derivative of formula (I) below: in which: R | 2012-11-08 |
20120282198 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF CAROB AS ACTIVE AGENT FOR ACTIVATING AQUAPORIN EXPRESSION - The invention relates to a cosmetic and/or pharmaceutical composition comprising, in a physiologically suitable medium, a carob peptide extract ( | 2012-11-08 |
20120282199 | UV PROTECTING COMPOSITION AND APPLICATOR - A composition that imparts protection from ultraviolet light to the skin of a subject is provided. The composition is suitable for delivery by a roller delivery apparatus that can be used to deliver the composition to areas of the body that are traditionally difficult to reach providing more complete and even coverage and enhancing the overall effect of protection from sunlight or other ultraviolet light. | 2012-11-08 |
20120282200 | UV ABSORBING DENTRITIC POLYETHER PREPARED BY POLYMERIZATION OF OXETANES - The present invention relates to a polymer comprising a hyperbranched dendritic polyether backbone covalently bonded via an oxygen bridge to at least one UV absorbing chromophore characterized in that the hyperbranched dendritic polyether backbone is obtainable by a ring-opening polymerization of at least one oxetane. Such polymers are particularly useful as UV-filter substances for example in compositions for the protection of the human skin and/or hair against harmful effects of sunlight. | 2012-11-08 |
20120282201 | NOVEL COMPOUNDS - The invention relates to novel polyglycerol based UV-filters as well as to topical compositions comprising such novel polyglycerol based UV-filters. Furthermore, the invention relates to the use of such novel polyglycerol based UV-filters to enhance the solubility of butyl methoxydibenzoylmethane or bis-ethylhexyloxyphenol methoxyphenyl triazine in cosmetic oils. | 2012-11-08 |
20120282202 | AQUEOUS COMPOSITION FOR TOPICAL APPLICATION, METHOD OF PREPARATION, USES AND DEVICE - An aqueous composition for topical application includes at least 60% w/w of a C1-C4 alkyl lactate ester, at least 1% w/w water, having a pH in the range from 1-6, and an effective amount of at least one physically acceptable antioxidant. A method is provided for the preparation, and the use of the composition for the treatment of fungus infections of nails and/or skin, in particular onychomycosis and tinea pedis, and an applicator device for performing such treatment. | 2012-11-08 |
20120282203 | PROPHYLACTIC OR AMELIORATING AGENT FOR PIGMENTATION - An object of the present invention is to provide a prophylactic or ameliorating agent for pigmentation having a novel scaffold and an external preparation for skin containing the same as a component. The object is achieved by providing a prophylactic or ameliorating agent for pigmentation comprising a compound represented by the following general formula (1), an isomer thereof, and/or a pharmacologically acceptable salt thereof and an external preparation for skin containing the same as a component: | 2012-11-08 |
20120282204 | Protection Against Sunburn And Skin Problems With Topical And Orally-Ingested Dosages Of Zeaxanthin - A carotenoid substance called zeaxanthin, when ingested orally at suitable dosages such as 30 to 100 mg/day for a span of 1 to 2 weeks, can provide effective protection against sunburns, and can give skin a darker tint that emulates a healthy suntan. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce: (i) a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan; (ii) a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure without any subsequent pain or discomfort, and without the subsequent peeling and flaking that characterizes sunburns; and, (iii) an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned. By reducing the amount of exposure to sunlight (or tanning lights) that are required to achieve a desired level of tanning, zeaxanthin can reduce the risks of skin cancer, premature aging or wrinkling, and similar skin problems. Since zeaxanthin also has retina-protecting properties and reduces the risk of a disease called macular degeneration, oral ingestion of these dosages of a zeaxanthin to enhance a tanned appearance and/or to protect against sun damage is believed to pose no health risks, and can offer several benefits due to the anti-oxidant and other activities of zeaxanthin. | 2012-11-08 |
20120282205 | ANHYDROUS LIQUID ANTIPERSPIRANT/DEODORANT COMPOSITION - An anhydrous liquid antiperspirant/deodorant composition comprising a carrier comprising a cation and/or zwitterion and a hydrogen bond donor, wherein an amount of carrier is greater than an amount of any other material in the composition, and an antiperspirant active. This represents a new delivery form for antiperspirant actives and/or deodorant actives. | 2012-11-08 |
20120282206 | METHOD OF MAKING AN ANHYDROUS LIQUID ANTIPERSPIRANT COMPOSITION - A method of producing an anhydrous antiperspirant composition comprising (a) providing a mixture of at least one antiperspirant active including a metal salt, and an anhydrous carrier for the at least one antiperspirant active in which the at least one antiperspirant active is dissolved, the carrier comprising a eutectic mixture of at least one basic compound selected from a basic amide and a basic amine and at least one member chosen from a cation and zwitterion; and (b) heating the mixture to form a stabilized eutectic system of the at least one antiperspirant active and the anhydrous carrier. Also, an anhydrous antiperspirant composition. | 2012-11-08 |
20120282207 | NATURAL ANTIMICROBIAL COMPOSITIONS - The present invention provides novel antimicrobial compositions. In one embodiment, the antimicrobial composition comprises an antimicrobial effective amount of a mixture comprising (a) two or more fatty acids, each of which is natural or naturally derived, and (b) at least one of (i) a natural or naturally derived product, (ii) an alcoholic solvent, or (iii) an organic acid or a salt thereof. The present invention also provides a product comprising a preservative effective amount of the aforementioned mixture. | 2012-11-08 |
20120282208 | METHOD AND CHEMICAL COMPOSITION FOR RESHAPING HAIR - The current invention comprises methods and compositions for straightening hair. Using embodiments of the current invention, curly hair can be effectively and safely straightened by a method that is milder and less damaging than the current art and does not employ ingredients such as formaldehyde and glutaraldehyde that are considered noxious and raise significant toxicological concerns. In one or more embodiments of the invention, a low concentration of sodium hydroxide (˜0.5-0.6%) is applied prior to the application of an oil (preferably a vegetable oil), followed by treatment with a flat iron, or similar, heated to ˜180-200° C. In one or more alternative embodiments of the invention, the sodium hydroxide and oil-containing compositions are combined and applied to the hair in a single step. The improvements extended by this invention beyond the current art include: reduced damage to hair; reduced potential for damage to the skin and eyes; elimination of noxious chemicals; avoidance of chemical systems that are banned in a number of countries; greater resistance to reversion; longer lasting results; and as a consequence of these considerations, potential for home (non-professional) usage. | 2012-11-08 |
20120282209 | MULTI-PHASE HAIR CONDITIONER - Packaged multi-phase hair conditioner comprising at least two visibly distinct phases, said composition comprising a nonionic surfactant and a water-swellable starch. | 2012-11-08 |
20120282210 | NOVEL ORGANOMODIFIED SILOXANES HAVING PRIMARY AMINO FUNCTIONS, NOVEL ORGANOMODIFIED SILOXANES HAVING QUATERNARY AMMONIUM FUNCTIONS AND THE METHOD FOR THE PRODUCTION THEREOF - The invention relates to a method for producing siloxanes selectively carrying primary amino groups by reacting them with ammonia, and to compounds produced in this way. | 2012-11-08 |
20120282211 | ANTIBODIES AND CONJUGATES FOR MODULATORS OF ANGIOGENESIS - We provide methods and compositions for the treatment of dysregulation of blood vessel growth by regulation of neovascularization. Embodiments accomplish this by restricting the diffusion and transport of therapeutic agents through conjugating them to polymers or polymer constructs while retaining the binding affinities and functions of the therapeutic agents. | 2012-11-08 |
20120282212 | AQUEOUS OLIGOMER/POLYMER EMULSION WITH CATIONIC FUNCTIONALITY - An aqueous emulsion comprising at least a covalently bound vinyl oligomer and vinyl polymer, wherein said vinyl oligomer comprises 5 to 85 mol % of vinyl monomers bearing quaternary ammonium ion functional groups or quaternisable amine functional groups and is obtained by a controlled radical polymerisation of at least one vinyl monomer via a reversible addition-fragmentation chain transfer mechanism in solution in the presence of a control agent and a source of free radicals; wherein said vinyl polymer is obtained by emulsion polymerisation of vinyl monomers in the presence of the vinyl oligomer; wherein the weight % ratio of vinyl oligomer to vinyl polymer is in the range of from 0.5:99.5 to 65:35. | 2012-11-08 |
20120282213 | Use of Polymeric or Oligomeric Active Ingredients for Medical Articles - The invention relates to the use of polymeric or oligomeric active ingredients having a biocidal effect as additives in the composition of medical articles. The invention further relates to medical articles that comprise such additives. | 2012-11-08 |
20120282214 | EXTERMINATION TECHNIQUES UTILIZING TERMITE EGG VOLATILE CALLING PHEROMONE AND QUEEN PHEROMONE - The present invention provides a termite attractant comprising 1-butanol, 2-butanol, or esters, ketones, ethers, carboxylic acids thereof, or salts thereof; a mimic termite-egg comprising the attractant; and a method for exterminating and controlling termites using the attractant or mimic termite-egg. | 2012-11-08 |
20120282215 | Vaccination of Cancer Patients - Pharmaceutical compositions containing (i) whole autologous cancer cells, whole allogeneic cancer cells, or a combination thereof; (ii) a colony stimulating factor (CSF); (iii) an interleukin; and (iv) a pharmaceutically acceptable carrier are described which are useful for inhibiting tumor growth, progression or recurrence or to inhibit metastases formation in solid cancerous tumors, leukemias, and lymphomas. | 2012-11-08 |
20120282216 | Composition and Method for Treating Cancer - Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same. | 2012-11-08 |
20120282217 | FOOT AND MOUTH DISEASE VIRUS (FMDV) CONSENSUS PROTEINS, CODING SEQUENCES THEREFOR AND VACCINES MADE THEREFROM - Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV. | 2012-11-08 |
20120282218 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS - New chiral and achiral oxy-substituted cyclopentyl pyridinone diketocarboxamides and their derivatives and methods for their preparations are disclosed. The compounds include tautomers, regioisomers and geometric isomers. These complex carboxamides are designed as inhibitors of HIV replication through inhibition of HIV integrase. The compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents, especially other anti-HIV compounds (including other anti-HIV integrase agents), which can be used to create combination anti-HIV cocktails. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described. | 2012-11-08 |
20120282219 | PEPTIDOMIMETIC PROTEASE INHIBITORS - The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. | 2012-11-08 |
20120282220 | GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES - Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis. | 2012-11-08 |
20120282221 | BROMO-PHENYL SUBSTITUTED THIAZOLYL DIHYDROPYRIMIDINES - This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections. | 2012-11-08 |
20120282222 | Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases - This invention relates generally to novel treatments to prevent neurodegeneration in the central nervous system comprising a therapeutic dosage of an estrogen receptor ligand and/or an immunotherapeutic compound, such as beta-interferon, to ameliorate the effects of the neurodegenerative disease and to stimulate repair. | 2012-11-08 |
20120282223 | Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid - The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD | 2012-11-08 |
20120282224 | MARKERS ASSOCIATED WITH RIBAVIRIN-INDUCED ANEMIA - The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful, inter alia, to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with ribavirin, and in methods for selecting the most appropriate therapy for such patients. | 2012-11-08 |
20120282225 | METHOD AND COMPOSITION FOR CREATING CONDITIONAL LETHALITY FOR VIRUS MUTANTS AND FOR ELIMINATING THE VIABILITY OF AN EUKARYOTIC CELL - Viral vectors are potential tools for eliminating the viability of eukaryotic cells in anti-cancer therapies since they can efficiently destroy the cancer cells and trigger an immune response against tumours. Typically viruses are not specific to cancer cells and all methods known in art aiming to the construction of cancer-specific viruses suffer from serious problems. The present invention presents a universal method to overcome these problems and is usable for any DNA virus replicating in nucleus or for any layered vector of RNA viruses. In this method the viral gene expression and/or replication will be blocked by the introduction of one or more aberrantly spliced introns into crucial gene expression units of the virus or vector. Lethal effect of these mutations is reverted in a controlled manner by the delivery of splice-switch oligonucleotide (s) correcting the introduced defects and restoring the biological functionality of the virus or vector, including cytolytic properties. | 2012-11-08 |
20120282226 | Tissue Products Derived From Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase - The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices. | 2012-11-08 |
20120282227 | METHODS AND COMPOSITIONS FOR THE INDUCTION OF HYPOTHERMIA - Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT3 receptor antagonist. Additional agents can be included in the composition including at least one of an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. The invention further recognizes that a two phase delivery of multidrug combinations, a rapid infusion of the composition to induce hypothermia followed by a period of slow infusion to maintain the hypothermic state for a sustained period of time. Using the two phase delivery method of the invention, the composition may comprise ethanol and, optionally, at least one of a vasoactive compound, an antiarrhythmic compound, a serotonin 5-HT3 receptor antagonist, an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. This two phase delivery method can be used to deliver any of the compositions of the invention and provides significant benefits to a patient. | 2012-11-08 |
20120282228 | METHOD OF PRODUCING PROGENITOR CELLS FROM DIFFERENTIATED CELLS - The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and/or tissues and/or organs derived therefrom, and kits comprising same. | 2012-11-08 |
20120282229 | NON-VIRAL DELIVERY OF TRANSCRIPTION FACTORS THAT REPROGRAM HUMAN SOMATIC CELLS INTO A STEM CELL-LIKE STATE - Disclosed herein are cellular compositions, stable continuous cell cultures, reporter cell lines, pharmaceutical preparations, cell penetrable pluripotent stem cells transcription factors and methods related thereto, related to reprogrammed somatic cells. | 2012-11-08 |
20120282230 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF GENETIC AND RETINAL DISEASE - A process of detecting the presence of or susceptibility to a disease involving the Frizzled-4 receptor is provided. The inventive method determines the presence or absence of one or more mutations in Frizzled-4 alone or in conjunction with other proteins such as Norrin and LRP5. The presence of a mutation predicts the presence of a disease or susceptibility to a disease. The inventive process further provides correction or prevention of a disease by administration of frizzled-4 to a subject to alter or maintain a physiological function. | 2012-11-08 |
20120282231 | HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 2012-11-08 |
20120282232 | Nutrient Hydration Bar - The method of the present invention comprises the administration of a complete matrix of natural whole food vitamins, minerals including necessary electrolytes, super anti-oxidants, proteins, amino acids, complex carbohydrates, fiber, lipids and bio-flavonoids with superior absorption, utilization and retention. The supplement provides a consumer or athlete enhanced hydration retention and energy which is extremely effective in enhancing exercise and sports performance. | 2012-11-08 |
20120282233 | FUNGI ANTAGONISTIC TO XYLELLA FASTIDIOSA - The disclosure describes fungal organisms and preparations useful for inhibiting infection by | 2012-11-08 |
20120282234 | Medium, Solutions And Methods For The Washing, Culturing And Storage Of White Blood Cells - White blood cell products and storage media for white blood cells are disclosed. The storage medium includes sodium chloride, sodium acetate, sodium citrate, sodium phosphate, magnesium chloride, potassium chloride, sodium bicarbonate, and glucose. White blood cells stored in such medium remain viable for at least up to 72 hours. | 2012-11-08 |
20120282235 | IMPLANTABLE PATCH AND SURGICAL KIT FOR PREPARATION THEREOF - Embodiments of the present invention include a surgical kit for preparation of a patch for implantation into a human body, characterized in that it comprises a package containing, on one hand, a synthetic substrate ( | 2012-11-08 |
20120282236 | METHOD OF DELIVERING OXYGEN USING PEG-HEMOGLOBIN CONJUGATES WITH ENHANCED NITRITE REDUCTASE ACTIVITY - The present invention relates generally to methods for delivering oxygen to tissue and reducing nitrite to nitric oxide in the microvasculature. Specifically, the present invention is directed towards using a deoxygenated pegylated hemoglobin conjugate having enhanced nitrite reductase activity to deliver oxygen to tissues. | 2012-11-08 |
20120282237 | USE OF PROTEIN ARGININE METHYLTRANSFERASES IN REGULATING HEMATOPOIETIC DIFFERENTIATION - The present invention relates to the manipulations of expression levels or enzymatic activities of PRMTs differentially regulate hematopoietic differentiation toward megakaryocytes or erythrocytes. The modulation of lineage fates of megakaryocyte-erythrocyte progenitors is useful for various purposes, including particular regulation of hematopoiesis for therapy and manufacture of individual blood cells for transplantation. | 2012-11-08 |
20120282238 | Use of Secreted Phospholipases A2 in the Diagnosis and Treatment of Malaria - The present invention relates to an in vitro method of diagnosis of a | 2012-11-08 |
20120282239 | NOVEL MANNANASE VARIANTS - The present disclosure provides novel mannanase variants which have an amino acid sequence that varies from that of the parent/wild type | 2012-11-08 |
20120282240 | THROMBIN ISOLATED FROM BLOOD AND BLOOD FRACTIONS - Methods, apparatus, and compositions related to generating and using thrombin. Methods include preparing a solution comprising thrombin by precipitating fibrinogen from a liquid comprising whole blood or a blood fraction. Precipitated fibrinogen is removed from the liquid to form a post-precipitation liquid that is incubated with calcium and a plurality of beads to form a clot. A solution comprising thrombin is separated from the clot. Thrombin prepared thereby can be used as a tissue sealant and in methods of applying a tissue sealant to subject, including application of an autologous tissue sealant. | 2012-11-08 |
20120282241 | Method of Treating Persistent Genital Arousal Disorder with a Neurotoxin - A method of controlling dysregulation of the dorsal cutaneous nerve of the clitoris and, in particular, a method for treating PGAD is provided. In one aspect, the method comprises administering a neurotoxin, such as a botulinum toxin, to the clitoral area of the human in need of treatment. | 2012-11-08 |
20120282242 | COMPOSITIONS, TARGETS, METHODS AND DEVICES FOR THE THERAPY OF OCULAR AND PERIOCULAR DISORDERS - Methods for treating ocular and periocular disorders by administration to a human patient of a therapeutically effective amount of a compound that modulates muscle action. | 2012-11-08 |
20120282243 | SOY SAUCE HAVING HYPOTENSIVE EFFECTS AND METHOD FOR PRODUCING THE SAME - The present invention provides soy sauce that comprises significant amounts of peptides, and, in particular, hypotensive peptide Gly-Tyr and hypotensive peptide Ser-Tyr, exhibiting a high degree of angiotensin-I-converting enzyme-inhibitory activity and has hypotensive effects while containing no hypotensive agent. Target soy sauce is obtained by mixing soy sauce koji having protease activity of 20 to 300 U/g koji with an aqueous common salt solution and subjecting the mixture to heated digestion, followed by compression filtration. Target soy sauce with a good flavor is obtained by adding soy sauce lactic acid bacteria and soy sauce yeast cells to the moromi mash after heated digestion, and subjecting the resultant to fermentation and maturation, followed by compression filtration. | 2012-11-08 |
20120282244 | USE OF AT LEAST ONE EXTRACT OF FLOWERS OF CAMELLIA JAPONICA ALBA PLENA FOR MOISTURIZING THE SKIN - The present invention relates to a cosmetic composition containing an extract of flowers of Camellia Japonica Alba Plena, as well as the cosmetic use thereof, for moisturizing and/or protecting human skin against drying. It also relates to an extract of flowers of Camellia Japonica Alba Plena, characterized in that it can be obtained by extraction of flowers by at least one alcoholic solvent. | 2012-11-08 |
20120282245 | BIOMARKERS AND ASSAYS FOR THE TREATMENT OF CANCER - This invention features methods for prognosticating the efficacy of a cancer treatment comprising administration of a lymphotoxin-β receptor (LT-β-R) using TRAF3, TRAF2, and/or p53 markers, as well as combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other agents. | 2012-11-08 |
20120282246 | Compositions and methods for antibody and ligand identification - Embodiments disclosed herein relate to methodology, and kits thereof for identifying particular disease-associated antibodies partially based on comparative binding to a mimotope array. Isolation of identified disease-associated antibodies and uses thereof are also described. | 2012-11-08 |
20120282247 | METHODS AND COMPOSITIONS INVOLVING PROTECTIVE STAPHYLOCOCCAL ANTIGENS, SUCH AS EBH POLYPEPTIDES - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2012-11-08 |
20120282248 | PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY - The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody. | 2012-11-08 |
20120282249 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY - Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo. | 2012-11-08 |
20120282250 | IL-21 ANTAGONISTS - Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases. | 2012-11-08 |
20120282251 | ANTI-CLUSTERIN ANTIBODIES AND ANTIGEN BINDING FRAGMENTS AND THEIR USE TO REDUCE TUMOR VOLUME - Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed. | 2012-11-08 |
20120282252 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes - The invention relates to the use of compounds of formula (I) or (II) | 2012-11-08 |
20120282253 | INTERLEUKIN-10 ANTIBODIES - The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology. | 2012-11-08 |
20120282254 | CD127 BINDING PROTEINS - Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis. | 2012-11-08 |
20120282255 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE - The present invention provides for compositions and methods for treating or preventing addictive and compulsive diseases and disorders, particular alcohol-related diseases and disorders, disclosed herein. The GLP activators of the present invention are effective against various alcohol and drug dependency diseases. In accordance with the invention, the present compositions and methods can be used to intercede upstream or downstream in the signal transduction cascade involved in GLP action to treat various alcohol and drug dependency diseases. In one embodiment, the synthesis or release of endogenous GLP can be stimulated. In another embodiment, the endogenous synthesis or release of another molecule active in the cascade downstream from GLP, (e.g., a molecule produced in response to GLP binding to a receptor), can be stimulated. Accordingly, the methods and compositions of the invention are useful for preventing, treating, diagnosing, or monitoring the progression various alcohol and drug dependency diseases disclosed herein. | 2012-11-08 |
20120282256 | CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN - The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the | 2012-11-08 |
20120282257 | SINGLE-CHAIN VARIABLE FRAGMENT (SCFV) ABLE TO RECOGNIZE AND BIND CD99 HUMAN PROTEIN - The present invention relates to a single-chain variable fragment (scFv) able to recognize an epitope of the extracellular domain of CD99 human protein. | 2012-11-08 |
20120282258 | CRLF2 IN PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - The invention relates to cytokine receptor-like factor 2 (CRLF2), and particularly certain mutant forms of CRLF2, as prognostic and therapeutic targets in precursor B-cell acute lymphoblastic leukemia (B-ALL). Mutant CRLF2 with a Phe232-Cys (F232C) mutation is overexpressed and constitutively activates STAT5 in a subset of B-ALL patients with particularly poor prognosis. Methods and compositions useful for identifying, inhibiting expression, and inhibiting activity of the mutant CRLF2 are provided. Also provided are methods and compositions useful for treating B-ALL. | 2012-11-08 |
20120282259 | MUTANT SMOOTHENED AND METHODS OF USING THE SAME - The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance. | 2012-11-08 |
20120282260 | ANTI-HERPES SIMPLEX VIRUS ANTIBODIES AND METHODS OF USE THEREOF - The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections. | 2012-11-08 |
20120282261 | Deuterated analogs of (4S)-4-Ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof - The present invention discloses: (i) two novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof. | 2012-11-08 |
20120282262 | USES AND COMPOSITIONS FOR TREATMENT OF PSORIASIS AND CROHN'S DISEASE - The invention provides methods, uses and compositions for the treatment of psoriasis or Crohn's disease. The invention describes methods and uses for treating psoriasis or Crohn's disease, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. The invention includes methods of improving patient reported outcomes using a human human TNFα antibody, or antigen-binding portion thereof, for the treatment of Crohn's or psoriasis. The invention also provides methods of improving fatigue or depression in patients having Crohns'. | 2012-11-08 |
20120282263 | COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION - The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation. | 2012-11-08 |
20120282264 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes. | 2012-11-08 |
20120282265 | MEDICAMENT AND A METHOD FOR REGULATION OF THE VASCULAR TONE - The method of treatment for diseases accompanied by disturbances of the vascular tone utilizes the use of ultra low doses of antibodies to a protein or a peptide involved in the vascular tone regulation or mediating the effects of other regulators; these antibodies are used in activated form produced by multiple subsequent dilution and external impact. | 2012-11-08 |